Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.66 |
| ▸ | STING1 | Q86WV6 | 14/20 | 0.47 |
| ▸ | DUT | P33316 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16575809 | 0.80 | DHFR (0.46) | DHFRSTING1DUT | |
| SCHEMBL2408425 | 0.80 | DHFR (0.75) | DHFRSTING1 | |
| SCHEMBL30968383 | 0.80 | DHFR (1.00) | DHFRSTING1 | |
| SCHEMBL1619438 | 0.80 | DHFR (1.00) | DHFRSTING1 | |
| SCHEMBL16558263 | 0.80 | DHFR (1.00) | DHFRSTING1 | |
| SCHEMBL21284217 | 0.79 | STING1 (0.71) | STING1 | |
| SCHEMBL18456892 | 0.79 | DHFR (0.43) | DHFRSTING1DUT | |
| SCHEMBL29359340 | 0.78 | STING1 (0.56) | STING1 | |
| SCHEMBL3225428 | 0.78 | DHFR (0.62) | DHFRSTING1 | |
| SCHEMBL3215086 | 0.78 | DHFR (0.56) | DHFRSTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087388-A1 | ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS | KOTRA LAKSHMI P | 2010-04-08 | — | — | US | claimed |
| WO-2007038860-A2 | ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS | UNIVERSITY HEALTH NETWORK (CA) | 2007-04-12 | — | — | WO | claimed |
| US-20220226239-A1 | POLYMERIC MICELLE COMPLEXES, FORMULATIONS, AND USES THEREOF | ARAVASC INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-8410075-B2 | Mannich base N-oxide drugs | CASCADE PRODRUG INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8293240-B2 | Method of treating drug-resistant cancer | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110206755-A1 | METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2011-08-25 | — | — | US | disclosed |
| EP-1545519-B1 | COMBINATION THERAPY FOR HYPERPROLIFERATIVE DISEASES | PFIZER (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7816319-B2 | Methods and products for manipulating uncoupling protein expression | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100087388-A1 | ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS | KOTRA LAKSHMI P | 2010-04-08 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| EP-2136626-A1 | MANNICH BASE N-OXIDE DRUGS | State of Oregon acting by and through the Oregon State Board of Higher Education on behalf of the University of Oregon (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20060140953-A1 | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with UCP and/or FAS antibody or other inhibitor, optionally with a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-29 | — | — | US | disclosed |
| WO-2005070126-A2 | METHODS AND COMPOSITIONS FOR TREATING HUMAN DISEASES AND WOUNDS WITH UCP AND FAS INHIBITORS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-1194168-A2 | METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6342485-B1 | ANTITUMOR AGENTS WITH NUCLEIC ACIDS | GMEINER, WILLIAM H. | 2002-01-29 | — | — | US | disclosed |
| WO-2000078941-A2 | METHODS AND PRODUCTS FOR MANIPULATING UNCOUPLING PROTEIN EXPRESSION | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2000-12-28 | — | — | WO | disclosed |
| US-5741900-A | REACTING PROTECTED FLUOROURIDINE WITH SUCCINIC ANHYDRIDE, ATTACHING TO LONG-CHAIN ALKYLAMINE CONTROLLED PORE GLASS IN ANHYDROUS PYRIDINE IN PRESENCE OF DIMETHYLAMINOPYRIDINE AND DIMETHYLAMINOPROPYL/ETHYLCARBODIIMIDE | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1998-04-21 | — | — | US | disclosed |
| US-5663321-A | INHIBITOR OF THYMIDYLATE SYNTHASE; ANTICANCER/ANTITUMOR AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-09-02 | — | — | US | disclosed |
| US-5614505-A | 5-FLUOROURIDINE OR 5-FLUORODEOXYURIDINE, DRUG DELIVERY, IMPROVED BIOAVAILABILITY, ANTICARCINOGENIC AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-03-25 | — | — | US | disclosed |
| US-5457187-A | Antitumor, anticarcinogeic agents | BOARD OF REGENTS UNIVERSITY OF NEBRASKA (US) | 1995-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087388-A1 | ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS | ITPA, DUT, MAOA | DHFR 73/4885STING1 798/4885DUT 2/4885 |
| US-20220226239-A1 | POLYMERIC MICELLE COMPLEXES, FORMULATIONS, AND USES THEREOF | PHOSPHO1, MUC1, MCL1 | DHFR 2633/4885STING1 3816/4885DUT 4502/4885 |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | ASAH2, MAN2B1, NNT | DHFR 540/4885STING1 3332/4885DUT 160/4885 |
| US-20060140953-A1 | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with UCP and/or FAS antibody or other inhibitor, optionally with a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor | FASN, FFAR2, FFAR1 | DHFR 104/4885STING1 2875/4885DUT 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.